On February 18, 2021 Oncopeptides AB reported that Year-end Report 2020 (Press release, Oncopeptides, FEB 18, 2021, View Source [SID1234575217]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial overview October 1 – December 31, 2020

Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 513.0 M (loss: 244.9)
Loss per share, before and after dilution, was SEK 7.59 (loss: 4.42)
On December 31 cash and cash equivalents amounted to SEK 840.3 M (926.2)
Significant events during the period October 1 – December 31, 2020

First patient enrolled in the phase 3 LIGHTHOUSE combination study in multiple myeloma
Phase 2 ANCHOR data presented at ASH (Free ASH Whitepaper)
Oncopeptides announced the intention to apply for conditional marketing authorization of melflufen in the EU
The FDA accepted IND application to initiate clinical studies with OPD5, the company’s second candidate drug
A capital markets day was arranged with more than 250 participants online
Full data set from phase 2 HORIZON study published in the Journal of Clinical Oncology
Oncopeptides entered into a €40 M loan agreement with the European Investment Bank (EIB)
Extraordinary General Meeting held in December resolved to implement a long-term incentive program for US employees
Financial overview of the group

Conference call for investors, analysts and the media

Year-end Report 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides Leadership team, Thursday February 18, 2021 at 14:00 (CET).

The conference call will also be streamed via a link on the website: www.oncopeptides.com.